THE MCMANUS GROUP for GENENTECH
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.
Foreign entity interest: 100% ownership by F. Hoffman-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, SUI
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
Health Issues HCR
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Foreign entity interest: 100% ownership by F. Hoffman-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, SUI
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas |
Taxation/Internal Revenue Code TAX
Issues related to tax exempt hospitals and charity care.
Foreign entity interest: 100% ownership by F. Hoffman-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, SUI
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARY GRACE DARCEY | — |
| JOHN MCMANUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.